Eyenovia receives Notices of Allowance on two patent applications

Eyenovia has received Notices of Allowance from the U.S. Patent and Trademark Office for two patent applications providing coverage on physiologic microdroplet ejection diameters and velocities, according to a press release.

Once the new patents are issued, Eyenovia will hold eight U.S. patents and 27 issued and allowed international patents in micro-therapeutic ophthalmic delivery.

“We are pleased that the USPTO continues to recognize the novel features of our piezo-print technology that has the ability to gently and efficiently deliver micro-therapeutic solutions to the eye,” Sean Ianchulev, MD, MPH, Eyenovia’s CEO and chief medical officer, said in the release. “With an expanding global intellectual property portfolio, we look forward to advancing our late-stage clinical assets for mydriasis, glaucoma and myopia into phase 3 development.”

Eyenovia has received Notices of Allowance from the U.S. Patent and Trademark Office for two patent applications providing coverage on physiologic microdroplet ejection diameters and velocities, according to a press release.

Once the new patents are issued, Eyenovia will hold eight U.S. patents and 27 issued and allowed international patents in micro-therapeutic ophthalmic delivery.

“We are pleased that the USPTO continues to recognize the novel features of our piezo-print technology that has the ability to gently and efficiently deliver micro-therapeutic solutions to the eye,” Sean Ianchulev, MD, MPH, Eyenovia’s CEO and chief medical officer, said in the release. “With an expanding global intellectual property portfolio, we look forward to advancing our late-stage clinical assets for mydriasis, glaucoma and myopia into phase 3 development.”